Home › Merck Provides Diabetes Portfolio Update and Underscores Comprehensive, Long-Term Commitment to Patients with Diabetes
 

Keywords :   


Merck Provides Diabetes Portfolio Update and Underscores Comprehensive, Long-Term Commitment to Patients with Diabetes

2015-09-17 14:30:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Presents Pivotal Data for Omarigliptin, Mercks Investigational Once-Weekly DPP-4 Inhibitor, and Additional Data from the TECOS CV Safety Trial, at European Association for the Study of Diabetes Annual Meeting KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, provided an update today on its diabetes portfolio and re-affirmed the companys comprehensive, long-term commitment to patients with diabetes. Merck has a proud history in helping patients with type 2 diabetes. Language: English Contact: MerckMedia:Pam Eisele, +1 (267) 305-3558Michael Close, +1 (310) 617-1067orInvestor:Justin Holko, +1 (908) 740-1879Teri Loxam, +1 (908) 740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with update comprehensive patients

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07Genesus to restructure with Canada ZF Investments
03.07Global trade, domestic policy: What's at stake for pork industry
03.07Over 20,000 Tesco staff to split 30m from share schemes
03.07Ex-Post Office chair denies hiding key Horizon report
03.07Print Quest invests in two more Miraclon Shine LED lamp kits
03.07ETI celebrates grand opening of new headquarters in Spain
03.07Mondi unveils FlexiBag Reinforced
03.07Nilpeter announces new partnership in the Philippines
More »